What happened with CHRS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Coherus Oncology now focuses on cancer immunotherapy after selling its biosimilar businesses. Its only approved commercial product is LOQTORZI (toripalimab), which treats adults with certain advanced or recurrent forms of nasopharyngeal carcinoma. Its U.S. approvals cover use with chemotherapy as an initial treatment and use alone after disease progresses following platinum-based chemotherapy.
LOQTORZI sales provide most of the company’s revenue. Coherus sells exclusively through specialty wholesalers, which resell to hospitals and clinics. McKesson, Cencora and Cardinal Health account for nearly all LOQTORZI revenue. Coherus licenses the drug from Junshi Biosciences, which supplies it, and pays Junshi royalties on net sales. The business therefore depends on both this supply relationship and physicians choosing the drug, supported by government and commercial insurance coverage and reimbursement.
Coherus is also developing casdozokitug and tagmokitug, both mid-stage clinical candidates, and plans to seek additional uses for toripalimab. These programs are not approved products: they need further clinical development and regulatory approval before they can generate product sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Coherus Oncology’s results hinge on LOQTORZI uptake and pipeline trials, making essential licensing partner Junshi Biosciences and Akeso’s approved penpulimab, a potential direct rival in nasopharyngeal cancer, key to watch.
Merck sells Keytruda while Coherus sells LOQTORZI, so their competing cancer medicines’ clinical results can influence treatment choices. Watch Keytruda trial results as Coherus seeks uses beyond its approved nasopharyngeal-cancer indications.
Bristol Myers Squibb competes with Coherus on two fronts: its marketed cancer medicine Opdivo rivals LOQTORZI in the broader checkpoint-treatment market, and its experimental CCR8 treatment could compete with tagmokitug. Watch its CCR8 trial progress for a potential rival to Coherus’s pipeline.
AstraZeneca’s Imfinzi competes with Coherus’s LOQTORZI in the broader U.S. market for cancer medicines targeting PD-1 or PD-L1. Imfinzi’s U.S. product sales are the relevant revenue line to watch, rather than AstraZeneca’s other cancer drugs.
Regeneron sells Libtayo against Coherus’s LOQTORZI in the broader U.S. cancer checkpoint-treatment market, but LOQTORZI’s approved niche is nasopharyngeal cancer. For this comparison, follow Libtayo rather than Regeneron’s EYLEA product sales.
GSK sells Jemperli while Coherus sells LOQTORZI, placing them in the broader U.S. PD-1 cancer-treatment market despite different approved uses. Watch Jemperli’s clinical expansion when assessing the competition facing Coherus’s plans for additional indications.
Agenus offers a clinical comparison for Coherus’s immunotherapy combinations: it develops CTLA-4 and PD-1 treatments, while Coherus already sells the PD-1 medicine LOQTORZI. Watch botensilimab plus balstilimab trial results; Agenus earns revenue from supplying that combination through authorized access programs, not marketing approval.
Arcus Biosciences offers a development comparison for Coherus’s cancer-treatment combinations: Arcus develops oncology programs including a licensed PD-1 agent, while Coherus sells toripalimab as LOQTORZI and develops further combinations. Watch Arcus’s cancer trial results rather than approved-product sales, since its business centers on clinical development.
Merck & Co., Inc. earningsMRK
Merck’s report will show Keytruda’s clinical progress, a measure of the competition Coherus Oncology faces as it pursues more uses for LOQTORZI.
Look for Keytruda trials advancing toward new cancer uses, alongside LOQTORZI’s current approvals for nasopharyngeal cancer. Clear progress would show that a rival is also extending its reach as Coherus seeks more indications; limited progress would mean less disclosed competitive advancement, not proof that LOQTORZI will win approval or patients in new uses.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report will show its CCR8 trial progress, a potential pipeline rival for Coherus Oncology’s tagmokitug.
Check whether Bristol Myers Squibb advances trials of its experimental CCR8 treatment, and compare that with Coherus’s tagmokitug, which is also in clinical development. Trial progress would show another company moving on the same target and could mean more future competition; no clear progress would mean no disclosed advance along that path, but it would not compare the drugs’ effectiveness.
Coherus Oncology, Inc. earningsThis company
Coherus Oncology relies on LOQTORZI sales for revenue, and this report will show whether sales growth is adding gross profit after royalties and supply costs.
Read LOQTORZI sales alongside gross margin. Rising sales with the margin holding would mean more product is selling without giving up the share left after Junshi royalties and manufacturing and distribution costs. Slower sales or a declining margin would point to weaker growth or pressure on the economics of each sale. Check whether the three wholesalers still account for most product revenue to gauge how dependent that growth is on a few channels.
